Search clinical trials for: Maximum tolerated dose (MTD)
Total 21201 results
-
University of Turin, ItalyCompletedMaxillary Transverse Deficiency (MTD)Italy
-
Basilea PharmaceuticaCompleted
-
Acea Bio (Hangzhou) Co., Ltd.Unknown
-
Nur Aishah Mohd TaibMalaysia Palm Oil BoardUnknownBreast Cancer FemaleMalaysia
-
SUNHO（China）BioPharmaceutical CO., Ltd.Not yet recruiting
-
Ain Shams Maternity HospitalRecruiting
-
Millennium Pharmaceuticals, Inc.CompletedDigestive System DiseaseUnited States
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Pharmacodynamics | SafetyNetherlands
-
King Faisal Specialist Hospital & Research CenterUnknownNeuroendocrine TumorsSaudi Arabia
-
OnxeoSpectrum Pharmaceuticals, IncCompletedDose Escalation: Solid Tumors | MTD: Soft Tissue SarcomasDenmark, United Kingdom
-
Novartis PharmaceuticalsCompletedAdvanced or Metastatic Breast CancerSpain, United States
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Unknown
-
ImmunityBio, Inc.Completed
-
University Hospital, BordeauxCompletedCarcinoma, Renal Cell | Malignant Advanced Solid TumorsFrance
-
AbbVieTerminated
-
Asana BioSciencesTerminatedMelanoma | Neoplasms | Colorectal Neoplasm | Carcinoma, Non-small Cell LungUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Samsung Medical CenterTerminatedPhase I: To Determine the Maximum Tolerated Dose (MTD) | Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/OxaliplatinKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedAdvanced Solid MalignanciesKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterStanford University; Juno Therapeutics, Inc.Active, not recruiting
-
Allarity TherapeuticsAmarex Clinical ResearchRecruiting
-
National Cancer Institute (NCI)CompletedCancer | Neoplasm Metastasis | NeoplasmUnited States
-
Hanmi Pharmaceutical Company LimitedCompletedAdvanced Solid MalignanciesKorea, Republic of
-
AbbVieTerminated
-
ImmunityBio, Inc.CompletedMalignant Solid TumourUnited States
-
HiberCell, Inc.CovanceCompletedRenal Cell Carcinoma | Gastric Cancer | Metastatic Breast Cancer | Small-cell Lung Cancer | Other Solid TumorsUnited States
-
Everfront Biotech Co., Ltd.Active, not recruitingAmyotrophic Lateral SclerosisTaiwan
-
Grupo Espanol de Investigacion en SarcomasActive, not recruitingDrug Use | GIST | Drug Toxicity | Metastatic Adult Soft Tissue Sarcoma | Maximum Tolerated DoseSpain
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy... and other collaboratorsTerminatedSARS-CoV 2 | COVID 19 | Viral InfectionUnited States
-
Novartis PharmaceuticalsCompletedColon CancerSpain, United Kingdom, France, Czechia
-
Boehringer IngelheimCompletedMalignant Solid TumourGermany
-
Zhejiang Haichang Biotech Co., Ltd.Not yet recruitingAdvanced Hepatocellular Carcinoma (HCC)
-
University of VirginiaActive, not recruitingGlioblastoma | Glioblastoma MultiformeUnited States
-
PeplinCompletedSuperficial Basal Cell CarcinomaUnited States
-
Glenmark Specialty S.A.RecruitingLymphoma | Advanced Solid TumorUnited States, India
-
Krankenhaus NordwestCompletedAdvanced Gastric Cancer | Advanced Cancer of the Esophagogastric JunctionGermany
-
University of VirginiaTerminatedBreast Cancer Female | Leptomeningeal MetastasesUnited States
-
KangLaiTe USACompletedNeoplasms | Solid Tumors Refractory To Standard TherapyUnited States
-
Standard Chem. & Pharm. Co., Ltd.Terminated
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)WithdrawnOsteosarcoma | Bone MetastasesUnited States
-
Monopar TherapeuticsRecruiting
-
HiberCell, Inc.CovanceTerminatedA Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Clear Cell Renal Cell Carcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Colo-rectal Cancer | Transitional Cell Carcinoma of the Bladder | Other Solid TumorsUnited States
-
Novartis PharmaceuticalsCompletedDose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)Neuroendocrine TumorsUnited States
-
The Cooper Health SystemTerminatedPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the PancreasUnited States
-
MovetisCompleted
-
Mersana TherapeuticsCompletedNeoplasm MetastasisUnited States
-
AbbVieTerminatedGastric Cancer | Colorectal Cancer (CRC)United States
-
Merck KGaA, Darmstadt, GermanyCompleted